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SUMMARY
In two prisons in Berlin, Germany, provision of sterile injection equipment for injecting drug
users (IDUs) started in 1998. To assess the programme’s impact, the frequency of injecting drug
use and syringe sharing, and the incidence of HIV, HBV, and HCV infection were determined in
a follow-up study. Of all IDUs (n=174), 75% continued to inject. After the project start the level
of syringe sharing declined from 71% during a 4-month period of previous imprisonment to 11%
during the first 4 months of follow-up, and to virtually zero thereafter. Baseline seroprevalences
for HIV, HBV, and HCV were 18, 53, and 82%. HIV and HCV seroprevalence at baseline was
significantly associated with drug injection in prison prior to the project start. No HIV and HBV
seroconversions, but four HCV seroconversions occurred. The provision of syringes for IDUs in
appropriate prison settings may contribute to a substantial reduction of syringe sharing.
However, the prevention of HCV infection requires additional strategies.
INTRODUCTION
Injection drug use in prison carries a substantial
risk of infection with bloodborne viruses such as
human immunodeficiency virus (HIV), hepatitis B
virus (HBV) and hepatitis C virus (HCV) [1–7].
Prevention strategies are needed to reduce the risk
of infection among incarcerated injecting drug
users (IDUs). Outside prisons, syringe exchange
programmes have played a key role in reducing the
spread of the viruses among IDUs [8–11]. Data on
the effectiveness of syringe exchange programmes
implemented inside prisons are scarce [12, 13]. In these
studies, laboratory tests to identify incident infections
with HIV, HBV, and HCV were not systematically
performed. Moreover, no data are available from
large metropolitan areas where IDUs may differ
significantly from those in other regions with respect
to drug use patterns, behavioural characteristics, and
prison experience.
In Berlin, Germany, the provision of sterile injec-
tion equipment was started in two prisons in 1998.
The objectives of the study were to investigate the
feasibility and safety of the project and to assess its
effects on drug use patterns, risk behaviour, and the
frequency of HIV, HBV, and HCV infection.
METHODS
Setting and study population
The project was implemented in a prison for females
(October 1998) and a prison for males (February
1999). All new inmates received information leaflets
and counselling on harm reduction issues, and on
the project itself. In the prison for females, three
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automatic dispensers were installed. They provided a
small package containing a sterile syringe and needle
and a skin disinfection pad in exchange for a used
syringe, or a dummy which is handed out to new
entrants. The dispensers were installed in places
generally not visible to prison staff. In the prison for
males, social workers from a non-governmental
organization exchanged sterile syringes and needles
for used equipment three times a week. Anonymity
and confidentiality was assured to the clients visiting
the room where the syringe exchange took place.
All inmates who had ever used illicit drugs (injection,
inhalational, or intranasal use of heroin or cocaine)
were eligible for participation in the study. New
entrants were consecutively recruited into the study.
After informed consent had been received, data on
sociodemographic and drug-use characteristics, and
risk behaviour before and during imprisonment were
obtained by trained external interviewers using stan-
dardized questionnaires. Laboratory testing for HIV,
HBV, and HCV seromarkers was offered to all partici-
pants. Pre-test and post-test counselling was performed
by members of the study team. After informed consent
had been obtained interviews and laboratory tests were
performed at baseline and at follow-up visits every 4
months and shortly before deferral. Questionnaires and
blood samples were coded, and all personal identifiers
were removed. These anonymized data were entered
into an Access database and analysed.
The study received institutional review board
approval from the Institute of Tropical Medicine,
Humboldt University Berlin, and ethical clearance
by the appropriate committee of the Department of
Justice, Senate of Berlin. The research conformed to the
principles embodied in the Declaration of Helsinki.
The study was carried out from October 1998 to
June 2001. During this time period 213 persons were
incarcerated in the two prisons, 174 of which partici-
pated in the study (response rate 82%). Respondents
did not differ significantly by age and gender from
non-respondents.
Laboratory methods
Enzyme-linked immunosorbent assay (ELISA) was
used to detect HIV antibodies (Sanofi Pasteur,
Freiburg, Germany), hepatitis B surface (HBs) anti-
gen, and anti-HBc (Abbott, Wiesbaden, Germany).
Anti-HBs was determined by radioimmunoassay
(Abbott). Positive HIV results were confirmed by
Western blot (Sanofi Pasteur). HCV antibodies were
detected by a third-generation ELISA (Ortho,
Neckargmünd, Germany). Positive or indeterminate
HCV results were confirmed by immunoblot (Abbott).
Statistical methods
To analyse associations between categorical variables
x2 tests or x2 tests for trend were used. For multi-
variate analysis (e.g. of determinants for HIV, HBV,
and HCV infection at baseline) forward stepwise
logistic regression was performed. The final models
(e.g. for risk factors for HIV or HCV infection at
baseline) were selected based on the likelihood ratio
statistic. For statistical analysis SPSS version 11.5 was
used (SPSS Inc., Chicago, IL, USA). In the follow-up
study, HIV, HBV, and HCV incidence rates (infec-
tions by 100 person-years) were calculated.
RESULTS
Baseline characteristics
Of the 174 participants (117 females, 57 males), 166
(95%) reported previous injection drug use. Table 1
shows the basic sociodemographic and behavioural
characteristics. The median age was 31 years (inter-
quartile range 27–34 years). Of the IDUs, 72% had
Table 1. Demographic and behavioural characteristics




















Injection drug use during previous
episodes of imprisonment
57
* Participants reporting previous injection drug use.
# Prior to current imprisonment.
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injected for o5 years. Injection drug use in the 6
months prior to imprisonment was reported by 91%.
Two thirds of the IDUs had ever injected with
syringes already used by another person (‘syringe
sharing’), and 17% had done so in the 6 months prior
to imprisonment. The majority of the IDUs (females
76%, males 88%) had previously been in prison.
At baseline, 71% of participants who had injected
drugs during previous periods of imprisonment (i.e.
before the project start) reported syringe sharing
during an average 4-month period in prison (Table 2).
Utilization of the syringe exchange programme and
adverse events
Overall, 3383 syringes were delivered to the prison
for females (October 1998 to June 2001), and 4571
syringes to the prison for males (February 1999 to June
2001). Substantial variations in the number of syringes
delivered per month were observed in the prison for
females although the number of incarcerated IDUs
was relatively stable. Peak use of the automatic
dispensers was in December 1999 (n=244 syringes)
and December 2000 (n=372). The number of dis-
pensed syringes was more constant over time in the
prison for males (range 150–250 per month).
No adverse events possibly related to the project
were observed (e.g. overall increase in injection drug
use, violence involving needles against staff or other
inmates).
Injection drug use and syringe sharing after project
start
Follow-up data were available from 124 participants
(81 females, 43 males) with a median follow-up time
of 12 months. Drop-outs were mainly due to pre-term
deferral or transfer to other institutions.
Injection drug use during follow-up was reported
by 67% of the females, and 90% of the males
(Table 2). Of the injectors, 95% used heroin, and
26% cocaine. The median frequency of injecting
(in the most recent 4-month period) was eight in
females (range 1–100), and 23 in males (range 4–200).
After the project start, 11% of the injectors reported
any syringe sharing (Table 2). This proportion did not
differ significantly by gender, age, or infection status at
baseline. Apart from two single later events, syringe
sharing only occurred during the first follow-up period.
Two of the eight individuals who had previously
used illicit drugs only by routes other than injection
started to inject drugs during follow-up. One person
injected only once during a 12-month follow-up, while
the other injected twice and was lost to follow-up.
Prevalence and determinants of HIV, HBV, and HCV
infection
At baseline the seroprevalence rates among the
IDUs were 18% for HIV, 53% for HBV, and 82%
for HCV. Only 9% of the inmates had evidence of
hepatitis B immunization (anti-HBs alone).
Table 2. Characteristics of imprisoned injecting drug users before and after start of





Follow-up period in prison
(median 12 months)
(n=124)
Injection drug use 91%* Females 67%
Males 90%





HIV 18% No seroconversion
HBV 53% No seroconversion
HCV 83% 4 seroconversions
(one infection definitely
acquired in prison)
* Injection drug use in previous 6 months (outside or inside prisons).
# Referring to individuals (denominator) who injected drugs during previous 4-month
periods of imprisonment (baseline investigation) or during 4-month follow-up periods.
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In univariate analysis, several variables such as year
of first injection drug use, age, overall frequency of
syringe sharing, previous imprisonment, and previous
injection drug use in prison were significantly associ-
ated with HIV, HBV, and HCV infection (data not
shown). Seroprevalences were inversely associated
with date of first drug injection (Fig.). HIV antibody
prevalence was 20% among participants who already
injected before 1995, but was only 4% among those
who started to inject after 1994 (P=0.02). In the latter
group, HCV seroprevalence was already 71% and
reached 97% among IDUs who started to inject
before 1990 (P<0.001).
In multivariate analysis, injecting drug use during
previous imprisonment was found to be an indepen-
dent predictor of HIV infection after adjusting for
time since first injection, and syringe sharing [adjusted
odds ratio (aOR) 2.3, 95% confidence interval (CI)
1.2–4.9], and of HCV infection (aOR 2.0, 95% CI
1.1–5.6). Year of first injection also remained a pre-
dictor of infection. The aOR in IDUs who started to
inject after 1994 (baseline category: start of drug
injection before 1990) was 0.2 (95% CI 0.04–0.8) for
HIV, 0.1 (95% CI 0.01–0.2) for HBV (after exclusion
of vaccinated IDUs), and 0.2 (95% CI 0.03–0.7)
for HCV.
Incidence of HIV, HBV, and HCV infection
During follow-up no HIV or HBV seroconversions
were observed. However, four out of 22 individuals
who were seronegative at baseline developed HCV
antibodies (incidence rate 18/100 person-years). In
three cases, HCV antibodies were detected at the first
follow-up (two males, one female). In another
male IDU, seroconversion occurred between the
third and fourth follow-up visit. All IDUs who
seroconverted denied sharing syringes while in prison.
However, three of them reported ‘frontloading’
(dividing up drug doses between two or more IDUs
involving a used syringe) or sharing of spoons for
drug preparation on several occasions in the months
preceding seroconversion. Other risk factors such
as tattooing, piercing or sexual risk behaviour were
denied.
DISCUSSION
The study shows that the provision of sterile injection
equipment in prisons is readily accepted by IDUs
and may contribute to a significant reduction of
syringe sharing over time. The baseline data under-
score previous findings that injection drug use during
incarceration is common, and may significantly
increase the risk of bloodborne infections [1–3, 6, 7].
The project was deliberately implemented in prisons
were illicit drugs are available despite measures
to control their inflow into prison. Therefore, the
relatively high levels of injection drug use throughout
the study period are not surprising.
Two individuals who had previously only inhaled
heroin reported injecting drug use on single occasions
during the study period. It cannot be ruled out
that the availability of sterile equipment may have
facilitated initiation of injecting drug use in these
persons. However, it is more likely that this finding
reflects the natural incidence of injection drug use
among inhalational heroin users in settings where
peers frequently inject [1, 5]. Overall, there was no
evidence that the availability of sterile syringes led to
an increase in drug consumption.
The implementation of the project was followed by
an impressive reduction of syringe sharing. During
4-month periods of incarceration prior to the project
start over 70% of drug injectors had shared syringes.
Only a minority of the participants reported syringe
sharing at the first follow-up, and during further
observation periods it virtually disappeared. A sub-
stantial reduction in the frequency of syringe sharing
among IDUs has also been reported from the projects
in Switzerland and Lower Saxony, Germany [12, 13].
Socially desirable responding in such studies may be a
problem, although efforts were made to minimize
























Year of first drug injection
1990–1994 After 1994
Fig. Seroprevalence of HIV (%), HBV ( ), and HCV (&)
infection among imprisoned injecting drug users according
to year of first drug injection.
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A strength of the study is the systematic testing for
HIV, HBV, and HCV infection during follow-up to
detect new infections. No HIV and HBV seroconver-
sions were observed. There is strong evidence from
routine data of medical departments in other prisons
in Berlin, Germany that some IDUs have definitely
acquired HIV infection or viral hepatitis while in
prison [14]. Unfortunately, no systematic studies
on incidence of HIV, HBV, and HCV infection
among IDUs incarcerated in prisons without syringe
exchange programmes have been published for
Germany. However, studies from other industrialized
countries reported relatively high incidences of these
infections among IDUs in prisons where no sterile
syringes are available [4]. Among Danish prisoners
HBV incidence was 16/100 person-years [15], and a
recent study in Scotland found an HCV incidence
of 29/100 person-years in individuals having shared
syringes during follow-up [7]. A limitation of our
study is the fact that the median time of follow-up
(12 months) was too short to demonstrate a long-term
preventive effect. If new infections occurred at the end
of the observation period the seroconversions would
not have been detected in prison. Nevertheless, the
lack of new infections in the project compares
favourably with incidence of HIV and HBV among
IDUs reported in previous studies inside and outside
prisons [15–17].
The significant reduction of syringe sharing in our
study is probably a result of the availability of sterile
injection equipment in the prisons. However, because
of lack of a control group it is not possible to directly
ascribe the fact that no HIV and HBV seroconver-
sions occurred due to this intervention. We cannot
rule out that other factors such as intensified coun-
selling of inmates about risks of parenterally trans-
mitted infections may have played a role in risk
reduction and lack of seroconversions in this study.
HCV antibody prevalence in our study was already
high at baseline. In addition, four seroconversions
were observed during follow-up, and at least one
infection was acquired after the project start. In many
places, HCV transmission is still a severe problem
among IDUs outside and inside prisons. The existing
prevention strategies including syringe exchange
programmes may not be sufficient to contain the
spread of HCV among IDUs [18]. Apart from syringe
sharing the practice of frontloading/backloading and
the sharing of other injection paraphernalia (e.g.
spoons, cookers) have to be considered as risk factors
[19–23].
In multivariate analysis, participants of our study
who started to inject after 1994 were significantly less
likely to test positive for HIV, HBV, or HCVmarkers.
This indicates a preventive effect of the harm
reduction measures, a full range of which have been in
operation in Berlin since the beginning of the 1990s.
However, the effect on hepatitis C was limited since
70% of IDUs who started to inject after 1994 still
acquired HCV infection.
In many prisons the prevention of bloodborne
infections among IDUs remains an important task.
In settings where it is feasible the provision of sterile
injection equipment may have its role among other
measures including intensified counselling, diversifi-
cation of treatment options (e.g. methadone main-
tenance), and hepatitis B immunization.
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